PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2025 Views
-
Last post by NHE
-
- 0 Replies
- 933 Views
-
Last post by NHE
-
- 0 Replies
- 9702 Views
-
Last post by NHE
-
- 0 Replies
- 1827 Views
-
Last post by Firidion
-
- 1 Replies
- 1300 Views
-
Last post by vesta
-
- 0 Replies
- 1963 Views
-
Last post by frodo
-
- 0 Replies
- 1879 Views
-
Last post by NHE
-
- 0 Replies
- 1430 Views
-
Last post by NHE
-
- 4 Replies
- 2361 Views
-
Last post by JohnC777